New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
12:17 EDTSGMOSangamo presents clinical data at CROI from SB-728-T program
Sangamo BioSciences announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections. The conference is being held in Boston from March 3 to 6. Data from an earlier Phase 1 clinical study in this program were also published in the March 6, 2014 issue of the New England Journal of Medicine. At CROI, data were reported from a Phase 1 /2 clinical trial, SB-728-1101, designed to evaluate the effect of increasing doses of Cytoxan preconditioning as a method to increase the numbers of circulating T-cells, including cells that were zinc finger nuclease modified at the CCR5 gene. The data demonstrate that increasing doses of Cytoxan preconditioning prior to a single infusion of SB-728-T led to a dose-dependent increase in both engraftment of CCR5-modified cells and notable increases in total CD4 cells above the baseline. In addition, researchers observed the greatest decrease in viral load during a treatment interruption from antiretroviral therapy at the highest Cytoxan dose (1.0 g/m2). Two of the three subjects treated at this dose remain on TI with detectable but stable VLs of several weeks duration. In addition, Sangamo updated the status of a subject from its SB-728-902, Cohort 5 study, who has demonstrated ongoing control of VL for 31 weeks without ART, and who remains on TI.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:10 EDTSGMOPiper Jaffray to hold a symposium
Subscribe for More Information
May 18, 2015
07:06 EDTSGMOSangamo presents new data from proprietary ZFP therapeutic programs
Subscribe for More Information
May 14, 2015
09:11 EDTSGMOSangamo updates HIV and cancer candidates results
Sangamo BioSciences announced clinical and preclinical data from several ZFP Therapeutic programs and collaborations demonstrating new evidence of viral control in HIV/AIDS. Two trials of the company's ZFP Therapeutic, SB-728-T, which is being developed as a potential 'functional cure' for HIV/AIDS, demonstrated the effect of SB-728-T treatment on both viral load control and HIV reservoir reduction in HIV-infected subjects. Data were also presented demonstrating the successful incorporation of ZFN-mediated genome editing into an existing clinical scale production method to improve the anti-tumor activity of a tumor infiltrating lymphocyte-based therapeutic for melanoma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use